Cigna (CI) Stock Forecast & Price Target

Cigna Group is poised for significant growth driven by the expansion of its Evernorth segment, which enhances patient satisfaction and lowers costs while improving health outcomes. The company is projected to achieve a stop-loss margin recovery that aligns with its healthcare segment's annual operating income growth expectations, predicting a recapture of 100 basis points by 2027, primarily in 2026. Additionally, Cigna's anticipated strong free cash flow is expected to support ongoing capital deployment, facilitating an expanded service offering that augments core growth trends.

The Cigna Group faces a negative outlook due to anticipated declines in its Evernorth Adjusted Operating Income (AOI), which is expected to decrease from approximately $3.5 billion in 2025 to about $2.75 billion in 2026, reflecting a year-over-year reduction of $758 million. This decrease is attributed to margin headwinds within its pharmacy benefit management (PBM) segment, including a projected decline in top customer AOI margins and the financial impact of transitioning to a rebate-free PBM model, which could reduce earnings by $500 million to $600 million in 2026. Additional risks include the slowing adoption of biosimilars, potential client losses impacting Evernorth's growth, and challenges in accurately pricing and managing healthcare costs, all of which contribute to an erosion of margins and an uncertain growth trajectory in the commercial market.